HSD3B1 genotype among metastatic castration-resistant prostate cancer patients: pharmacodynamics and clinical outcomes after treatment with abiraterone plus prednisone
Bastos, D. A.; Jardim, D. L.; Zylberberg, R.; Santos, E. X.; Inoue, L. T.; Camargo, A. A.
Show abstract
The impact of HSD3B1 (1245 A>C) polymorphism on clinical outcomes of patients with metastatic castration-resistant prostate cancer (mCRPC) treated with abiraterone remains under debate. We investigated how HSD3B1 genotypes influence serum levels of testosterone, dehydroepiandrosterone sulfate (DHEA-S), abiraterone, delta-4-abiraterone (D4A) and clinical outcomes of mCRPC patients treated with abiraterone plus prednisone (AAP). Blood samples from 42 mCRPC patients were collected during AAP treatment. HSD3B1 genotypes were determined by Sanger sequencing and analyses were made comparing AA versus AC+CC groups. PSA decline equal or above 50% from baseline (PSA50) at any time, Time to PSA progression (TPP), and Overall Survival (OS) were evaluated. Frequencies of AA, AC and CC HSD3B1 genotypes were 50.0%, 33.3%, and 16.7%, respectively. The HSD3B1 genotype did not influence steroids or drug levels during AAP treatment. PSA50 at any time was 71.4% for AA and 42.9% for the AC+CC group (p=0.061). Median TPP was similar between groups. The AA group had a median OS of 21.3 months, which was not reached by the AC+CC group (p=0.15). PSA50 at any time was lower in the AC+CC compared to AA group, though not statistically significant. The HSD3B1 genotype was not associated with TPP nor with OS.
Matching journals
The top 8 journals account for 50% of the predicted probability mass.
Similar papers in this journal
- Role of CYP3A5 in modulating androgen receptor signaling and its relevance to African American men with prostate cancer 93%
- Genomic profile in TGCT Mexican patients reveals a potential biomarker of sensitivity to platinum-based therapy 91%
- High accuracy indicators of androgen suppression therapy failure for prostate cancer – a modeling study 90%
Similar papers in this journal
- Mapping Molecular Diversity in Prostate Cancer with a Combined Multiplex IHC and RNA-ISH Assay 93%
- Use of Droplet Digital PCR for Consistent Detection of TMPRSS2:ERG Gene Fusion Transcripts Initiated In Vitro 92%
- RELA is Sufficient to Mediate Interleukin-1 (IL-1) Repression of Androgen Receptor Expression and Activity in LNCaP Disease Progression Model 91%
Similar papers in this journal
- Association of the rs1042522 SNP with prostate cancer risk: a study of cancer tissues, primary tumor cultures and serum samples from a European Caucasian population 94%
- 5hmC-profiles in Puerto Rican Hispanic/Latino men with aggressive prostate cancer 92%
- Osthole Suppresses Prostate Cancer Progression by Modulating PRLR and the JAK2/STAT3 Signaling Axis 92%
Similar papers in this journal
- Estrogen receptor β exerts tumor suppressive effects in prostate cancer through repression of androgen receptor activity 93%
- Glycoprofiling of proteins as prostate cancer biomarkers: a multinational population study 93%
- The impact of positive surgical margin parameters and pathological stage on biochemical recurrence after radical prostatectomy: a systematic review and meta-analysis 92%
Similar papers in this journal
- Applying a genetic risk score for prostate cancer to men with lower urinary tract symptoms in primary care to predict prostate cancer diagnosis: a cohort study in the UK Biobank 90%
- A prospective validation of nomograms based on BC-116 and BC-106 urine peptide biomarker panels for bladder cancer diagnostics and monitoring 89%
- Peroxisomal β-oxidation enzyme, DECR2, regulates lipid metabolism and promotes treatment resistance in advanced prostate cancer 87%
"Similar papers" are the closest papers from that journal in the model's embedding space. They show what the match is built on, but the ranking comes mostly from a classifier over the whole training set, not from these examples alone.